

*Renal Cell Cancer and the General Medical Oncologist: Where We Are and Where We're Headed*

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

1. A retrospective analysis by Silberstein and colleagues evaluating patients with RCC who underwent cytoreductive nephrectomy at Memorial Sloan-Kettering Cancer Center (MSKCC) reported which of the following to be the factor most likely to lead to patients suffering a complication during the perioperative period?
  - a. Poor risk by MSKCC criteria
  - b. Lactate dehydrogenase level
  - c. Patient performance status
2. The ongoing S-TRAC trial is evaluating the efficacy and safety of \_\_\_\_\_ versus placebo for patients with localized RCC who are at high risk for disease recurrence.
  - a. Axitinib
  - b. Sorafenib
  - c. Sunitinib
  - d. All of the above
3. Results from the Phase II RECORD-3 trial, which compared sequential first-line everolimus and second-line sunitinib to the standard therapy of first-line sunitinib and second-line everolimus for patients with mRCC, indicated that the treatment paradigm in this setting should remain sunitinib followed by everolimus.
  - a. True
  - b. False
4. The Phase III INTORSECT trial of temsirolimus versus sorafenib for patients with mRCC for whom prior sunitinib therapy had failed reported a statistically significant progression-free survival advantage for temsirolimus compared to sorafenib.
  - a. True
  - b. False
5. A Phase III trial of axitinib versus sorafenib as first-line therapy for mRCC reported a 3.6-month improvement in median progression-free survival in favor of axitinib, but this improvement was not statistically significant.
  - a. True
  - b. False
6. The Phase II ASPEN trial is evaluating \_\_\_\_\_ versus sunitinib for patients with nonclear cell mRCC.
  - a. Everolimus
  - b. Temsirolimus
  - c. Both a and b
7. Results from a retrospective analysis of patients with mRCC treated on the single-arm IL-2 SELECT trial reported that \_\_\_\_\_ may predict better response to IL-2 therapy.
  - a. Clear cell histology
  - b. Nonclear cell histology
  - c. PD-L1/PD-L3 tissue expression
8. Which of the following metabolic abnormalities may be associated with the administration of everolimus?
  - a. Hyperglycemia
  - b. Hypercholesterolemia
  - c. Hypertriglyceridemia
  - d. All of the above
9. Although results from the Phase III ARISER trial of the anti-G250 antibody girentuximab versus placebo as adjuvant therapy for high-risk clear cell RCC were negative, a post hoc analysis suggested that patients with a higher carbonic anhydrase score fared better with regard to disease-free survival and overall survival than patients with a low carbonic anhydrase score.
  - a. True
  - b. False
10. The ongoing Phase III PROTECT study is evaluating pazopanib versus placebo as adjuvant treatment for localized RCC.
  - a. True
  - b. False